Literature DB >> 18389323

Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes.

Imke Satzger1, Bernward Völker, Andre Meier, Alexander Kapp, Ralf Gutzmer.   

Abstract

BACKGROUND: Previous studies described various criteria in sentinel lymph nodes (SLN) of melanoma patients that predict the involvement of further, nonsentinel lymph nodes (NSLN). Such criteria may facilitate the selection of patients who might benefit from a completion lymph node dissection (CLND). However, it is currently unclear which parameters are most important.
METHODS: A total of 180 melanoma patients with positive SLNB and subsequent CLND were investigated. Histopathologic parameters in the SLN were systematically evaluated and compared with regard to NSLN positivity. Twenty-eight of these patients (16.0%) had positive NSLN.
RESULTS: By univariate analysis several criteria with regard to tumor burden and location of melanoma cells in the SLN correlated with NSLN involvement, such as positivity by hematoxylin-eosin (H&amp;E) staining (P < .001), largest diameter of clusters (P < .001), capsular involvement (P = .001), extranodal extension (P < .001), and tumor penetrative depth (P < .001). Multivariate analysis revealed three independent parameters: (1) positivity of the SLN by H&amp;E staining (versus by immunohistochemistry alone), (2) relative tumor burden > 10% of total lymph node tissue, and (3) perinodal intralymphatic tumor. In 23 of 28 patients with positive NSLN the SLN was positive by H&amp;E staining, in 15 of 28 patients the relative tumor burden was > 10%, and 13 of 28 showed perinodal intralymphatic tumor. In 5 of 28 patients with NSLN involvement, these three parameters were negative.
CONCLUSIONS: Histopathologic examination of the SLN can identify patients at risk for NSLN positivity.

Entities:  

Mesh:

Year:  2008        PMID: 18389323     DOI: 10.1245/s10434-008-9888-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Rare presentations of primary melanoma and special populations: a systematic review.

Authors:  Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2014-12       Impact factor: 2.339

2.  Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.

Authors:  Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

Review 3.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

4.  Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

Authors:  Rajmohan Murali; Alistair J Cochran; Martin G Cook; Joseph D Hillman; Rooshdiya Z Karim; Marc Moncrieff; Hans Starz; John F Thompson; Richard A Scolyer
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

Review 5.  Update and Review on the Surgical Management of Primary Cutaneous Melanoma.

Authors:  Solmaz Niknam Leilabadi; Amie Chen; Stacy Tsai; Vinaya Soundararajan; Howard Silberman; Alex K Wong
Journal:  Healthcare (Basel)       Date:  2014-06-10

6.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.